Displaying items by tag: Department of Medicine

A UAB researcher suggests that autoimmune disease therapy may be an effective treatment for idiopathic pulmonary fibrosis.
HIV/AIDS is the leading cause of death worldwide for women ages 15-44 years, and UAB serves as a site for the latest study by the Microbicide Trials Network, which has previously studied this new approach with positive results in other female age groups.
UAB presented an observational study at this week’s annual American Society of Clinical Oncology meeting in Chicago that indicates a more rapid decline in Medicare costs and patient resource utilization during implementation of a lay navigation program.
David Pollock, Ph.D., professor in the Division of Nephrology, recently visited Cuba with a delegation from the American Physiological Society to sign a historic agreement for research collaboration with leaders of the Cuban Society of Physiological Sciences.
UAB presented an observational study at this week’s annual American Society of Clinical Oncology meeting in Chicago that indicates a more rapid decline in Medicare costs and patient resource utilization during implementation of a lay navigation program.
In late March, physicians at the University of Alabama at Birmingham carefully threaded a one-way valve the size of a black-eyed pea into the lower lobe of Dennis Bullock’s left lung. Bullock, a 67-year-old emphysema patient, was the fourth person at UAB to receive the experimental Zephyr® endobronchial valve.
William C. Bailey, professor in the Division of Pulmonary, Allergy and Critical Medicine at the University of Alabama at Birmingham, has been awarded a Lifetime Achievement Award for 50 years of exemplary service by the Tulane Medical Alumni Association.
UAB and CreakyJoints, an online, non-profit, patient support community, are launching Arthritis Power — the first patient-centered research registry for arthritis, bone and inflammatory skin conditions — to securely collect health data from tens of thousands of arthritis patients to support future research.
UAB was part of a promising international study of a combination therapy for patients with the most common cystic fibrosis mutation.
Page 37 of 51